Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Dezember 2018 08:00 ET | Quelle: Interface Biologics Inc

Interface Biologics Announces New V.P., Business Development

TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
27. November 2018 08:00 ET | Quelle: Interface Biologics Inc

Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases

TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
09. Februar 2016 07:30 ET | Quelle: Interface Biologics Inc.;Fresenius Medical Care

Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care

TORONTO, CANADA--(Marketwired - Feb. 9, 2016) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
13. Januar 2015 07:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics Announces Series B Financing Round With DSM and BDC Capital

TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) - Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of...
14. Januar 2014 07:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics and Q3 Medical Devices Sign Agreement to Develop Next Generation Drug Coated Balloon with Kinesyx(TM) Technology

TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) - Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization...
05. März 2013 07:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General

TORONTO, ONTARIO--(Marketwire - March 5, 2013) - Editors Note: There is a photo associated with this press release. Interface Biologics Inc. (IBI), a privately held...
02. Oktober 2012 07:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics Appoints Sandra Beach Lin to Board of Directors

TORONTO, ONTARIO--(Marketwire - Oct. 2, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
06. September 2012 07:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics Announces Licensing Partner AngioDynamics has Received FDA Clearance for BioFlo(TM) PICC with Endexo(TM) Technology

TORONTO, ONTARIO--(Marketwire - Sept. 6, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
25. Oktober 2011 08:30 ET | Quelle: Interface Biologics Inc.

Interface Biologics Announces Licensing Agreement With Navilyst Medical

TORONTO, CANADA--(Marketwire - Oct. 25, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
12. Juli 2011 08:30 ET | Quelle: Interface Biologics Inc.

Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement

TORONTO, ONTARIO--(Marketwire - July 12, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...

Nächste Seite